Michel L - Search Results

1

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.

Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, Harrison M, Mooney T, McMichael JF, Luo J, Tao Y, Goncalves R, Schlosberg C, Hiken JF, Saied L, Sanchez C, Giuntoli T, Bumb C, Cooper C, Kitchens RT, Lin A, Phommaly C, Davies SR, Zhang J, Kavuri MS, McEachern D, Dong YY, Ma C, Pluard T, Naughton M, Bose R, Suresh R, McDowell R, Michel L, Aft R, Gillanders W, DeSchryver K, Wilson RK, Wang S, Mills GB, Gonzalez-Angulo A, Edwards JR, Maher C, Perou CM, Mardis ER, Ellis MJ. Li S, et al. Among authors: michel l. Cell Rep. 2013 Sep 26;4(6):1116-30. doi: 10.1016/j.celrep.2013.08.022. Epub 2013 Sep 19. Cell Rep. 2013. PMID: 24055055 Free PMC article.

2

Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck.

Touma W, Koro SS, Ley J, Wildes TM, Michel L, Tao Y, Adkins D. Touma W, et al. Among authors: michel l. Oral Oncol. 2014 Sep;50(9):895-900. doi: 10.1016/j.oraloncology.2014.06.017. Epub 2014 Jul 15. Oral Oncol. 2014. PMID: 25037161 Free PMC article.

3

Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC.

Zhang K, Jones L, Lim S, Maher CA, Adkins D, Lewis J, Kimple RJ, Fertig EJ, Chung CH, Van Tine BA, Ellis MJ, Herrlich A, Michel LS. Zhang K, et al. Among authors: michel ls. Oncotarget. 2014 Oct 15;5(19):9281-94. doi: 10.18632/oncotarget.2423. Oncotarget. 2014. PMID: 25238142 Free PMC article.

4

Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers.

Kremer JC, Prudner BC, Lange SES, Bean GR, Schultze MB, Brashears CB, Radyk MD, Redlich N, Tzeng SC, Kami K, Shelton L, Li A, Morgan Z, Bomalaski JS, Tsukamoto T, McConathy J, Michel LS, Held JM, Van Tine BA. Kremer JC, et al. Among authors: michel ls. Cell Rep. 2017 Jan 24;18(4):991-1004. doi: 10.1016/j.celrep.2016.12.077. Cell Rep. 2017. PMID: 28122247 Free PMC article.

5

Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk.

Kaklamani VG, Baddi L, Liu J, Rosman D, Phukan S, Bradley C, Hegarty C, McDaniel B, Rademaker A, Oddoux C, Ostrer H, Michel LS, Huang H, Chen Y, Ahsan H, Offit K, Pasche B. Kaklamani VG, et al. Among authors: michel ls. Cancer Res. 2005 Apr 15;65(8):3454-61. doi: 10.1158/0008-5472.CAN-04-2961. Cancer Res. 2005. PMID: 15833881

6

A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas.

Bean GR, Kremer JC, Prudner BC, Schenone AD, Yao JC, Schultze MB, Chen DY, Tanas MR, Adkins DR, Bomalaski J, Rubin BP, Michel LS, Van Tine BA. Bean GR, et al. Cell Death Dis. 2016 Oct 13;7(10):e2406. doi: 10.1038/cddis.2016.232. Cell Death Dis. 2016. PMID: 27735949 Free PMC article.

7

Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma.

Redlich N, Robinson AM, Nickel KP, Stein AP, Wheeler DL, Adkins DR, Uppaluri R, Kimple RJ, Van Tine BA, Michel LS. Redlich N, et al. Among authors: michel ls. Cell Death Dis. 2018 Jan 5;9(1):5. doi: 10.1038/s41419-017-0029-0. Cell Death Dis. 2018. PMID: 29305574 Free PMC article.

8

Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma.

Robinson AM, Rathore R, Redlich NJ, Adkins DR, VanArsdale T, Van Tine BA, Michel LS. Robinson AM, et al. Cell Death Dis. 2019 Nov 14;10(11):867. doi: 10.1038/s41419-019-2098-8. Cell Death Dis. 2019. PMID: 31727874 Free PMC article.

9

Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer.

Dong Y, Li A, Wang J, Weber JD, Michel LS. Dong Y, et al. Cancer Res. 2010 Jul 1;70(13):5465-74. doi: 10.1158/0008-5472.CAN-10-0173. Epub 2010 Jun 22. Cancer Res. 2010. PMID: 20570903

10

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.

Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson R, Pipkorn P, Michel LS, Ley J, Oppelt P, Dunn GP, Barnell EK, Spies NC, Lin T, Li T, Mulder DT, Hanna Y, Cirlan I, Pugh TJ, Mudianto T, Riley R, Zhou L, Jo VY, Stachler MD, Hanna GJ, Kass J, Haddad R, Schoenfeld JD, Gjini E, Lako A, Thorstad W, Gay HA, Daly M, Rodig SJ, Hagemann IS, Kallogjeri D, Piccirillo JF, Chernock RD, Griffith M, Griffith OL, Adkins DR. Uppaluri R, et al. Among authors: michel ls. Clin Cancer Res. 2020 Oct 1;26(19):5140-5152. doi: 10.1158/1078-0432.CCR-20-1695. Epub 2020 Jul 14. Clin Cancer Res. 2020. PMID: 32665297 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

793 results

Search Page